The Semelil (ANGIPARS™) ameliorates cardiac functional disturbances after experimental chronic myocardial infarction model in rabbit

Myocardial infarction (MI) is one of the important causes of mortality in all populations. Some herbal drugs have been utilized for the treatment of MI. This research was designed to study the cardioprotective effects of Semelil (ANGIPARS™), a novel herbal drug, in male rabbits. Twenty New Zealand white rabbits were randomly allocated into four groups: control vehicle, sham vehicle, ischemia vehicle, and Semelil 10 mg/kg. Ischemia was created by complete occlusion of the left anterior descending coronary artery (LADC). Semelil was intraperitoneally injected for 2 weeks in the treatment group. Functional, biochemical, and histological investigations were used for discovering protective effects of Semelil. Based on the results of this study, Semelil ameliorated the echocardiographic pattern. In addition, treatment with Semelil amended levels of serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, and cardiac troponin T comparing to the ischemia group. Morphological data revealed that Semelil could save cardiomyocyte against myocardial infarction problems. The results indicate that Semelil has cardioprotective effects that may be created by its anti-inflammatory and antioxidant actions.